neuromuscular effect of rocuronium in patients with obstructive jaundice

A randomized trial to study whether neuromuscular effect of rocuronium is prolonged in patients with obstructive jaundice, in order to reduce the risk of postoperative residual neuromuscular block.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000371099

Enrollment

Registered

2010-05-10

Start date

2010-02-18

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primnary purpose of this study was to investigate whether the neuromuscular effect of rocuronium is prolonged in patients with obstructive jaundice. We hypothesized that neuromuscular effect of rocuronium is prolonged in patients with obstructive jaundice, just as it does in patients with hepatic or renal dysfunction.

Interventions

rocuronium will be injected intravenously only once when the patient is in stale anesthesia. The dosage is 0.9 mg/kg, three times of 95% effective dose (0.3mg/kg).

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

patients for upper abdominal surgery with or without obstructive jaundice

Exclusion criteria

Age<65 yr or >18 yr; body mass index (BMI) <24.9 or >18.5; history of diabetes, cardiovascular, respiratory, or renal diseases; hepatic encephalopathy, psychiatric illnesses, or neuropathy; complication of acute cholangitis, gastrointestinal bleeding, or ascites; electrolyte or acid-base disturbance, sepsis; receiving drugs known to interfere with neuromuscular transmission.

Outcome results